Companion diagnostics have had a profound impact on the way in which cancer is treated – and the promise of truly personalised medicine is edging closer towards reality.
The pace of change is accelerating and while it brings many new opportunities, the ever-increasing complexity also creates multiple challenges – for physicians as well as drug manufacturers.
In this latest paper from the Ipsos Oncology Centre of Excellence, Pieter De Richter – Head of Ipsos’ Molecular Diagnostics (MDx) Portfolio – draws on current data from our Oncology MDx Monitor to show how this complexity can be harnessed to achieve success for all stakeholders, including the patient.
Communicating Public Health: Conversations about the COVID-19 pandemic - Report 2
Humour, strong emotions and videos about hand-washing in evidence as the British public turns to social media during lockdown according to this second in our series of four reports for Future Care Capital from Ipsos MORI.